Skip to main content
European Commission logo print header

3D Bioprinting of JOINT Replacements

Article Category

Article available in the following languages:

Personalised ‘living implants’ offer hope for osteoarthritis sufferers

Regenerative medicine promises better treatment for joint damage than the only current option of a full joint replacement. In a paradigm shift away from purely biological approaches, 3D-JOINT used bioprinting to mimic the biomechanical properties of cartilage.

Health icon Health

Joint damage causes pain and loss of function, often impairing mobility. It can also trigger a vicious cycle of increasing degeneration of the cartilage and bone underlying joints, leading to the disabling disease of osteoarthritis (OA). OA is the leading cause of frailty among the elderly, occurring in over 40 million people in Europe. With our rapidly ageing society, this prevalence is set to dramatically rise, increasing the associated healthcare costs. The 3D-JOINT project, supported by the European Research Council, developed personalised ‘living implants’ from simultaneously 3D-bioprinted resorbable thermoplastic polymer filaments and cell-laden hydrogels to promote joint regeneration. “Depositing biomaterials and cells layer-by-layer allowed control over their placement and organisation. This precision resulted in durable tissue with much better biomechanical properties,” explains Jos Malda, project coordinator. “Technology to fabricate implants this way had not been developed before.”

Advancing state of the art

Transplanting specialist cells is a better solution than simply repairing diseased or damaged tissues, as it allows these cells to aid in natural joint regeneration. The use of donor stem cells, as a single step approach, has been explored before. However, transplantations have not created stable enough implants, nor adequately matched the contours of the joint. 3D-JOINT’s bioprinting approach was able to meet both criteria. To treat cartilage defects, cells are harvested from patients, multiplied in the laboratory, then implanted back into the defective area, keeping them in place using a soft matrix and/or fibrin glue. Firstly, to validate the biofabrication approach and to assess the mechanical integrity of the implants, cylindrical composite constructs were developed. These contained integrated bone and cartilage printed from biomaterials and cells. For subsequent generations, the constructs were scaled up, and more intricately shaped implants were made. 3D-JOINT’s converged bioprinting process improved the integration of cartilage and bone components, while enabling control over the simultaneous deposition of microfibres and cells. The microfibres added to the structural integrity of the implant as they were fused into a calcium phosphate-based upper cartilage part and a lower bone part, in which these fibres are anchored. This ensured the integration of the two parts. The hydrogel polymers provided an ideal scaffold for new cartilage formation with the regenerative cells deposited across a tissue-specific matrix throughout the gel. “Computational models and advances in microfibre design, inspired by the orientation of collagen fibres in native tissue, significantly increased both the compressive and shear properties of these implants,” reports Malda. Testing their approach in equine models, the team improved the design of micro-scale plug implants used to treat osteochondral injury, and these were shown to withstand the challenging environment of the stifle joint. Following this, larger personalised osteochondral constructions, based on CT scans and consisting of a fibre reinforced cartilage layer, were fabricated and mechanically tested in an ex vivo goat model.

Knowledge-sharing for future developments

Knowledge acquired during 3D-JOINT has already been introduced to the next generation of researchers through the Utrecht University Biofabrication Master’s programme, a yearly summer school and an E-course. Through BioArchitect, a Eurostars project, 3D-JOINT has also helped REGENHU, a world-leading manufacturer of high-end bioprinting equipment, to develop a commercial converged bioprinting system. “We are now focused on developing our flexible bone-inducing biomaterial as a durable treatment for hip dysplasia,” says Malda. As for the repair of larger cartilage defects, the team are preparing a larger equine clinical study, before looking to start human trials.


3D-JOINT, osteoarthritis, joint, regenerative medicine, cartilage, bone, cell, hydrogel, 3D, printing, bioprinting, microfibre, stem cells, biomaterial, biofabrication

Discover other articles in the same domain of application